HIV patients at risk of exhausting treatment options

A small but growing proportion of HIV infected patients in the United Kingdom may be in danger of exhausting current treatment options, says a paper published online by the BMJ today.

Highly active antiretroviral therapy (HAART) has had a dramatic impact on the health of individuals infected with HIV. But some patients experience problems while receiving HAART and may have to switch drugs on one or more occasions, raising the concern that these patients may exhaust all currently available treatment options.

Researchers at six large HIV centres in southeast England monitored 16,593 individuals who had attended one of the centres for care between 1996 and 2002.

They found that, although patients infected with HIV are becoming increasingly exposed to different antiretroviral treatments over time, immunological and virological profiles of these patients continue to improve.

Currently little evidence exists to indicate that a large proportion of patients are starting to experience therapeutic failure, say the authors. However, for a small number, treatment options are in danger of becoming exhausted.

New drugs with low toxicity, which are not associated with cross resistance to existing drugs, are urgently needed for such patients, they conclude.

Contact:
Caroline Sabin, Professor of Medical Statistics and Epidemiology, Department of Primary Care and Population Sciences, Royal Free and UC Medical School, London, UK
Tel: +44 (0)20 7830 2239 ext 4752
Email: [email protected]

Click here to view full paper

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
African nations must take ownership of HIV response to reduce disease burden